Although the healthcare community commonly recognizes obesity as a disease, it is not yet universally recognized as such.2,3 Increased recognition of obesity as a disease could not only have a positive effect on the treatment of patients with obesity, but it could help to eliminate weight-bias in healthcare settings and promote more empathetic, non-stigmatizing interactions between providers and patients.
Advertisement
The drug significantly reduced the annual rate of moderate or severe exacerbations in eosinophilic phenotypes.
A study of real-world data found that tolvaptan reduced long-term kidney function decline in ADPKD.
Using serum cystatin C as a biomarker for AKI could prove to be a valuable addition to diagnostic protocols, a study reports.
Dr. Eva Blondeaux discusses RRSO timing and fertility in young BRCA+ women and the need for shared, personalized decisions.
In the phase 3 REGENCY trial, adding obinutuzumab to standard therapy for lupus nephritis led to better renal outcomes.
Risk-reducing surgery improves survival in young BRCA1/2 carriers, study shows, guiding counseling for high-risk patients.
A preclinical mouse study showed hemostasis restoration, as well as use for active bleeding and internal bleeding prevention.
A study found low rates of IgAN in the EU, but lower biopsy rates during the COVID-19 pandemic may have delayed diagnoses.
Advertisement
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
A preclinical mouse study showed hemostasis restoration, as well as use for active bleeding and internal bleeding prevention.
A novel complement-targeting agent shows impressive efficacy and safety without immunosuppression of the classical pathway.
Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE.
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
A cohort study of extended-phase anticoagulation following acute management was performed in the phase III EINSTEIN Jr trial.
Fidanacogene elaparvovec gene therapy is a safe and effective treatment for patients with hemophilia B, research shows.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.